Tuberculosis and transplantation: Battling the opportunist

Clinical Infectious Diseases

Volumn 48, Issue 12, 2009, Pages 1666-1668

  Kumar, Deepali ^a   Humar, Atul ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b 4103A RTF ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; ISONIAZID; OKT 3; QUINOLONE; RIFABUTIN; RIFAMPICIN;

CYTOKINE RELEASE; DELAYED DIAGNOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG SAFETY; HUMAN; INCIDENCE; INFECTION RISK; LIVER TOXICITY; NOTE; ORGAN TRANSPLANTATION; POSTPRIMARY TUBERCULOSIS; PRIORITY JOURNAL; RISK FACTOR; SCREENING TEST; SENSITIVITY AND SPECIFICITY; TUBERCULIN TEST; TUBERCULOSIS;

HUMANS; INCIDENCE; ORGAN TRANSPLANTATION; RISK FACTORS; TUBERCULOSIS;

EID: 66949125431     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/599036     Document Type: Note

References (12)

1. Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis 1998;27:1266-77.
2. Torre-Cisneros J, Doblas A, Aguado JM, et al. Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort. Clin Infect Dis 2009; 12:1657-65 (in this issue).
3. Centers for Disease Control and Prevention. Transplantation-transmitted tuberculosis-Oklahoma and Texas, 2007. MMWR Morb Mortal Wkly Rep 2008; 57:333-6.
4. Mycobacterium tuberculosis.Am J Transplant 2004;4:37-41.
5. Shankar MS, Aravindan AN, Sohal PM, et al. The prevalence of tuberculin sensitivity and anergy in chronic renal failure in an endemic area: tuberculin test and the risk ofpost-trans- plant tuberculosis. Nephrol Dial Transplant 2005; 20:2720-4.
6. Weir E, Fisman DN. Latent tuberculosis: revised treatment guidelines. CMAJ 2003; 169: 937-8.
7. Manuel O, Humar A, Preiksaitis J, et al. Comparison of Quantiferon-TB gold with tuberculin skin test for detecting latent tuberculosis infection prior to liver transplantation. Am J Transplant 2007; 7:2797-801.
8. Singh N, Wagener MM, Gayowski T. Safety and efficacy of isoniazid chemoprophylaxis administered during liver transplant candidacy for the prevention of posttransplant tuberculosis. Transplantation 2002; 74:892-5.
9. Jahng A, Tran T, Bui L, et al. Safety of treatment of latent tuberculosis infection in compensated cirrhotic patients during transplant candidacy period. Transplantation 2007;83:1557.
10. Lee J, Yew WW, Wong CF, Wong PC, Chiu CS. Multidrug-resistant tuberculosis in a lung transplant recipient. J Heart Lung Transplant 2003;22:1168-73.
11. Muñoz P, Rodriguez C, Bouza E. Mycobacterium tuberculosis infection in recipients of solid organ transplants. Clin Infect Dis 2005;40:581-7.
12. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-62.